Statements of historical fact also may be deemed to be forward-looking statements. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof.
This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. For further information, please visit Important Cautions Regarding Forward-looking Statements
These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.īacterin's Medical Device division develops, employs, and licenses coatings for various medical device applications. In attendance will be Dan Goldberger, CEO Robert DiSilvio, President Gregory Juda, CSO and Melanie Head, VP of Sales.īacterin International Holdings, Inc. (NYSE MKT:BONE) develops, manufactures and markets biologic products to domestic and international markets. The NASS Annual Meeting Technical Exhibits will be open November 12 th-13 th 9:00AM – 5:00PM PST, and November 14 th 9:00AM – 1:30PM PST at the Moscone Center in San Francisco, CA.īacterin's executive officers will be on hand to answer questions about Bacterin's spine product portfolio including OsteoSponge ®, OsteoSelect ® DBM Putty, OsteoWrap ®, OsteoSTX™, and the new 3Demin™ product family. The new 3Demin™ line of products will be featured at Bacterin's booth, number 2004. The NASS Annual Meeting is renowned as, "The world's largest spine meeting and exhibition." Bacterin's 3Demin™ product family will be showcased to a targeted spine demographic that is influential in surgical supply purchasing decisions.
(NYSE MKT:BONE), a leader in the development of bone graft material and bioactive coatings for medical applications, today announced the first public presentation of a unique new product line for use in spinal procedures, the 3Demin™ product family, which will be displayed at the 2014 North American Spine Society (NASS) Annual Meeting. 4, 2014 (GLOBE NEWSWIRE) - Bacterin International Holdings, Inc.
0 kommentar(er)
